Echosens

20/02/2026

🎉 Echosens is proud highlight Good Samaritan Hospital as part of the !

The team leverages FibroScan® to enhance their metabolic health approach by providing non-invasive, point-of-care liver and spleen health assessments for patients at risk for MASLD/MASH.

By integrating FibroScan®, their team is helping patients get answers faster, monitor disease progression, and engage in meaningful conversations about prevention and treatment.

👏 Congratulations, Good Samaritan Hospital! Echosens is honored to support your mission to improve liver and metabolic health outcomes for patients in Indiana.

18/02/2026

The conference begins today and runs until February 20 in Madrid!
Come meet our team at booth #1 to discover the latest product innovations and learn about the new generation of FibroScan® devices equipped with Guided VCTE™ technology. Stop by for a scan demonstration!

13/02/2026

🎉 Celebrating the Opening Ceremony of our first Center of Excellence in APAC!

On February 6, 2026, we proudly inaugurated the Center of Excellence at Yonsei University Hospital.

This achievement was made possible thanks to the strong partnership and continuous support of Prof. Seung Up Kim, with whom we share a clear and ambitious mission:
1️⃣ Educate local General Practitioners in Korea on the essential role of identifying and screening MASLD patients through our Local Liver Education Program.
2️⃣ Support hepatologists across APAC by sharing best‑practice workflows and demonstrating the clinical value of FibroScan® in the management of liver health.

This Center of Excellence marks a significant step forward in advancing liver disease awareness, early diagnosis, and clinical collaboration throughout the region.

Excited for the journey ahead and the positive impact we will continue to create together!

11/02/2026

📰 A new clinical study is now available:
In patients with severe alpha-1 antitrypsin deficiency (AATD), this recent study shows that LSM by FibroScan® is proving to be an outstanding prognostic tool for predicting major adverse liver outcomes.

Current recommendations support systematic screening and longitudinal monitoring with clear LSM cut-off values to guide clinical decisions—below 8 kPa, 8-13 kPa, and 13 kPa or higher.
These benchmarks help determine when patients need closer monitoring, specialist referral, or might benefit from liver-directed therapies.

➡️ Learn more here:
🔸English: https://www.echosens.com/clinical-utility-vcte-alpha-1-antitrypsin-deficiency/
🔸Español: https://www.echosens.com/es/utilidad-clinica-vcte-alfa-1-antitripsina/
🔸Français : https://www.echosens.com/fr/mesure-vcte-deficit-alpha-1-antitrypsine/
🔸Italiano: https://www.echosens.com/it/utilita-clinica-vcte-alfa-1-antitripsina/
🔸Deutsch: https://www.echosens.com/de/vcte-alpha-1-antitrypsin-mangel/

09/02/2026

How does a leading endocrinologist approach MASLD and MASH screening with FibroScan®?

📹 Hear it straight from the source—Martin Grajower, MD.

“And frankly, I don’t remember anybody ever saying no.”

For more insights from Dr. Grajower, read “Unlocking Better Patient Outcomes: Why Liver Health Is the Key to Metabolic Wellness”: https://www.echosens.com/en-us/wp-grajower/

04/02/2026

🌍 Today is World Cancer Day.
Behind every diagnosis is a person, a family, a story. But often, liver cancer remains silent until it’s too late — leading to a life-altering diagnosis at an advanced stage.

Raising awareness and improving access to non-invasive diagnostic solutions like FibroScan® are key steps toward earlier intervention and better patient outcomes.

➡️ Let’s turn awareness into action and help build a future together where cancer is detected earlier and treated better.


World Cancer Day

30/01/2026

💡 “My feeling was that if I'm going to be the best possible diabetologist out there, I should do everything that I can, and so I decided to get the FibroScan® because I really felt it would enhance my care of my patients, not just for diagnosing fatty liver disease, but whatever implications patients with fatty liver disease have.” — Martin Grajower, MD

For Dr. Grajower, the turning point came when he recognized how frequently MASLD appears in patients with diabetes and prediabetes—and how limited traditional testing is in detecting early disease. As outlined in his white paper, integrating FibroScan® meant moving from guesswork to objective data that could truly guide comprehensive metabolic care.

🔗 Check out the full white paper “Unlocking Better Patient Outcomes: Why Liver Health Is the Key to Metabolic Wellness”: https://www.echosens.com/en-us/wp-grajower/

28/01/2026

Great insights from Meena Bansal, MD on metabolic dysfunction-associated steatotic liver disease (MASLD) and how patients can better understand liver function tests. Thank you, Dr. Bansal, for breaking down the nuances of AST and ALT levels—and for highlighting the value of tools like FibroScan® in liver health assessment.

💡 Valuable takeaway about liver enzyme results: “A truly normal, slam-dunk level of AST is less than 20 U/L for women and 30 U/L for men,” Dr. Bansal explains—an important detail that can easily be overlooked. “This is lower than you might see as the ‘range of values’ when you review your own laboratory tests. That is because the ranges provided on your lab reports represent what the values are for 95% of the population getting their blood tests done at that specific lab, and so these normal ranges can vary across the region and country.”

Read more: https://www.womansworld.com/wellness/normal-ast-levels-by-age-and-the-link-to-fatty-liver-disease

What your blood test results really mean—and why postmenopausal women need to pay attention.

26/01/2026

👏 A must-read for anyone working in metabolic health.

Endocrinologist Martin Grajower powerfully captures a truth we can no longer afford to overlook: liver health is metabolic health.

Despite MASLD affecting the majority of patients with type 2 diabetes or obesity, routine liver assessment is still far from standard care—and that gap has real consequences.

His article underscores the urgent need for routine, reliable liver assessment, earlier detection, and data-driven conversations that help patients truly understand their health.

At Echosens, we’re grateful for clinicians like Dr. Grajower who are bringing urgency and clarity to the role of liver health in metabolic disease. This kind of leadership moves the entire field forward and helps ensure more patients get the early detection and support they deserve. https://kevinmd.com/2025/12/the-livers-role-in-metabolic-disease.html

MASLD is a critical driver of metabolic disease, not just a complication. Routine liver screening is essential for early intervention in diabetes and cardiovascular disease. Learn why.

23/01/2026

We are proud to highlight JDJ Gastro, PLLC as a member of our ! 🧡

With FibroScan® as part of their practice, David E Johnson, MS, PA-C and the team are expanding access to liver care in Kentucky and helping more patients take control of their liver and metabolic health.

FibroScan® empowers JDJ Gastro to detect risks to liver health earlier, track progress over time, and provide personalized care that has a real impact on their community's health.

👏 Congratulations to the team – their dedication to patient-centered care is inspiring, and we’re honored to partner with their practice!

21/01/2026

Early detection of metabolic dysfunction-associated steatotic liver disease (MASLD) is still far too rare—not because clinicians aren’t looking, but because the tools they’ve traditionally relied on simply aren’t built to catch it. Standard liver function tests like ALT and AST miss up to 80% of patients with MASLD, and ultrasound can miss nearly 40% of early disease. That means fibrosis often progresses silently until it’s irreversible—a missed opportunity not just for liver health, but for comprehensive metabolic care.

🎥 In this clip, leading endocrinologist Martin Grajower, MD, explains how a precise, point-of-care, non-invasive tool—FibroScan®—is helping clinicians move beyond the limitations of traditional testing and bring liver health into the metabolic conversation.

🔗 For more in-depth insights from Dr. Grajower, read “Unlocking Better Patient Outcomes: Why Liver Health Is the Key to Metabolic Wellness”: https://www.echosens.com/en-us/wp-grajower/

19/01/2026

Last week, our global teams from EMEA, LATAM, and APAC gathered in the Paris region for the 2026 annual Echosens Sales & Marketing Meeting.

Two productive days focused on sharing our 2026 strategy and aligning on ambitious goals for the year ahead.
It was a fantastic opportunity to exchange ideas and strengthen collaboration between our diverse teams!

Many thanks to Pr Angelo Armandi, for his passionate speech about the multiple benefits of spleen stiffness measurement in clinical practice!